Generics Bulletin is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

Hikma Starts Added-Value Push With Heparin Syringes

Executive Summary

Heparin marks the start of Hikma’s pre-filled syringe portfolio in the US as the company looks to add value and differentiation to its injectables portfolio and pipeline, commercial and business development head Dan Motto told Generics Bulletin.

You may also be interested in...



Hikma Eyes Another Hybrid Injectable With Arecor

London-listed Hikma has signed a second partnership agreement with Arecor, proposing to co-develop a 505(b)(2) hybrid injectable product for the US market.

Hikma And Civica Ship Eight Essential Injectables

Hikma and Civica Rx have announced the launch of a first wave of eight essential injectable medicines, including heparin, as part of a deal struck between the two firms earlier this year.

Meitheal’s Heparin Launch Builds On Nanjing King-Friend Backing

Launching eight heparin vial presentations in the US is evidence of how injectables specialist Meitheal Pharmaceuticals intends to leverage the vertically-integrated production capacity of its Chinese parent group NKF.

Related Content

Topics

Related Companies

Latest News
See All
UsernamePublicRestriction

Register

GB149177

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel